Curability of advanced indolent or low-grade follicular lymphomas: Time for a new paradigm?

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 14-16

  Cabanillas, Fernando ^a,b,c  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTIOCYTIC LYMPHOMA; HISTOLOGY; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; NEPHROBLASTOMA; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUMOR REGRESSION;

COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; PROGNOSIS; SURVIVAL RATE;

EID: 84871763008     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7527     Document Type: Note

References (14)

1. Portlock C, Rosenberg S: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979
2. Brice P, Bastion Y, Lepage E, et al: Comparison in low tumor burden follicular lymphomas between an initial no treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires. J Clin Oncol 15:1110-1117, 1997
3. Ardeshna K, Smith P, Qian W: An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): A preliminary analysis. Blood 116, 2010 (abstr 6)
4. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
5. DeVita VT Jr, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy. Lancet 1:248-250, 1975
6. Cabanillas F, Velasquez WS, Hagemeister FB, et al: Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79:1024-1028, 1992
7. Coiffier B, Thieblemont C, Van Den Neste E, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010
8. Frei E 3rd, Gehan EA: Definition of cure for Hodgkin's disease. Cancer Res 31:1828-1833, 1971
9. Barr PM, Lazarus HM: Follicular non-Hodgkin lymphoma: Long-term results of stem-cell transplantation. Curr Opin Oncol 20:502-508, 2008
10. Khouri IF: Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 390-397, 2006
11. Thomson KJ, Morris EC, Milligan D, et al: T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28:3695-3700, 2010
12. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
13. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001
14. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 25:2554-2559, 2007